Current antiviral agents FactFile: 2000-2001 update. Part I - Herpesviruses, hepatitis viruses and respiratory viruses

International Antiviral News

Volumn 8, Issue 10, 2000, Pages 155-164

  Kinchington, D ^a   Balzarini, J ^a   De Clercq, E ^a   Daluge, S ^a   Field, H J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO 5,6 DICHLORO 1 BETA DEXTRO RIBOPYRANOSYL 1H BENZIMIDAZOLE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; ARBIDOL; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; BETA DEXTRO 2,6 DIAMINOPURINE DIAXOLANE; BWS 524 W 91; CIDOFOVIR; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; GW 273175X; IMIQUIMOD; ISIS 13312; LAMIVUDINE; LOBUCAVIR; NETIVUDINE; OSELTAMIVIR; PENCICLOVIR; PIRODAVIR; PLECONARIL; RESIQUIMOD; RIBAVIRIN; RUPINTRIVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOSTREX;

ANTIVIRAL ACTIVITY; CHICKENPOX; CLINICAL TRIAL; CONDYLOMA; CYTOMEGALOVIRUS INFECTION; DRUG RESEARCH; DRUG STRUCTURE; HEPATITIS B; HEPATITIS C; HERPES; HERPES SIMPLEX KERATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT INDICATION; VIRUS HEPATITIS; VIRUS INFECTION;

EID: 0034519853     PISSN: 09652310     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Selectivity of action of an antiherpetic agent 9-(2-hydroxyethoxymethyl)guanine
2. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy
3. Antiretroviral activity and pharmacokinetics in mice of oral bis (pivaloyloxymethyl)-9-(2-phosphonylmethoxethyl)adenine, the bis (pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl) adenine
4. Inhibitory effect of 9-(2-phosphonylmethoxyethyl) adenine (PMEA) on human and duck hepatitis B virus infection
5. Antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease
6. Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor
7. Antiviral activity of 1-adamantanamine (amantadine)
8. Viral respiratory infections in the community: Epidemiology, agents and interventions
9. The study of effect of a new antiviral drug arbidol on different stages of viral reproduction
10. Arbidol
11. (E)-5-(2-bromovinyl)-2′-deoxyuridine: A potent and selective antiherpes agent
12. Antiviral efficacies of famciclovir, valaciclovir, and brivudin in disseminated herpes simplex virus type 1 infection in mice
13. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines
14. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS
15. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus
16. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats
17. Perspectives for the treatment of hepatitis B virus infections
18. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir
19. The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5yl)]cytosine
20. Favorable interaction of β-L-(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus
21. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
22. Efficacy of the carboxylic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
23. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1yl)guanine; penciclovir]
24. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections
25. 2′-Fluoro-5-iodo-aracytosine, a potent and selective antiviral agent
26. Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial
27. FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B
28. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
29. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region
30. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015
31. Trisodium phosphonoformate, a new antiviral compound
32. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections
33. A new nucleoside analog, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, highly active in vitro against herpes simplex virus types 1 and 2
34. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS
35. Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37
36. Expression of human cytomegalovirus UL36 and UL37 genes is required for viral DNA replication
37. Development of benzimidazoles for HCMV
38. Synthesis and evaluation of a series of 1-benzimidazole pyranosides as anti-human cytomegalovirus agents
39. Effects of 5-iodo-2-deoxyuridine (IDU) on herpesvirus synthesis and survival in infected cells
40. Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: A multicenter placebo-controlled trial
41. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection
42. Treatment of genital warts with an immune-response modifier (imiquimod)
43. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
44. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
45. Cyclobut-A and cyclobut-G: Broad-spectrum antiviral agents with potential utility for the therapy of AIDS
46. Lobucavir
47. Benzamidazoles for the treatment of human cytomegalovirus
48. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects
49. Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex
50. n-Docosanol 10% cream in the treatment of recurrent herpes labialis: A randomised, double-blind, placebo-controlled study
51. 5-Alkynyl pyrimidine nucleosides as potential selective inhibitors of varicella-zoster virus
52. Multiple dose netivudine, a potent anti-varicella zoster virus agent, in healthy elderly volunteers and patients with shingles
53. Influenza neuraminidase inhibitors posessing a novel hydrophobic interaction ion the enzyme active site: Design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity
54. GS4104: A new orally administered anti-influenza drug candidate
55. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture
56. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial
57. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity
58. Intranasal pirodavir (R77,975) treatment of rhinovirus colds
59. Picomavirus inhibitors: Trifluoromethyl substitution provides a global protective effect against hepatic metabolism
60. Antipicornavirus drugs: Current status
61. Immunomodulating and antiviral activities of the imidazoquinoline S-28463
62. Broad-spectrum antiviral activity of virazole: 1-β-D-Ribofuranosyl-1,2,4,-triazole-3-carboxamide
63. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview
64. Rimantadine: A clinical perspective
65. Antiherpesviral and anticellular effects of 1-β-D-arabinofuranosyl-E-5-(2-halogenovinyl) uracils
66. Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults
67. In vitro evaluation of the antiviral activity of SP-303, and Euphorbiaceae shrub extract, against a panel of respiratory viruses
68. Safety and efficacy of Virend for topical treatment of genital and anal herpes simplex lesions in patients with AIDS
69. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-α for treatment of drug-resistant and -sensitive herpes simplex virus infections
70. Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172)
71. Amino acid esters prodrugs of aciclovir
72. Valacidovir: A review of its antiviral activity, pharmacokinetic properties, and clinical efficacy
73. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses
74. The antiviral activity of 9-β-D-arabinofuranosyladenine (ara-A)
75. Vidarabine (Vira-A): Pharmacology and clinical experience
76. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug
77. Antiviral treatment with WIN 54 954 reduces mortality in murine coxsackievirus B3 myocarditis
78. Rational design of potent sialidase-based inhibitors of influenza virus replication
79. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections